Butylated Hydroxyanisole vs Recombinant Bovine Somatotropin: which is worse?
Quick answer: Recombinant Bovine Somatotropin carries the heavier risk profile. Butylated Hydroxyanisole is — in the EU and — in the US; Recombinant Bovine Somatotropin is — in the EU and — in the US.
| Property | Butylated Hydroxyanisole | Recombinant Bovine Somatotropin |
|---|---|---|
| EU status | — | — |
| US status | — | — |
| Risk level | — | — |
| Banned in | Japan (banned for use in foods containing fats and oils) | European Union, Canada, Japan, Australia, New Zealand |
| Restricted in | European Union (restricted; banned in baby food), United Kingdom, Australia/New Zealand (ADI-based limits) | — |
| Category | additive | additive |
| Where it hides | — | — |
What is Butylated Hydroxyanisole?
Butylated hydroxyanisole (BHA) is a synthetic phenolic antioxidant preservative derived from petroleum. It is a mixture of two isomeric compounds (2-BHA and 3-BHA). BHA prevents fats and oils from oxidizing (going rancid), extending shelf life. Its chemical formula is C11H16O2.
What is Recombinant Bovine Somatotropin?
Recombinant bovine somatotropin (rBST) is the synthetic version of bovine growth hormone (BST), naturally produced by the pituitary gland in cattle. The recombinant version is produced using genetically engineered bacteria and is injected into dairy cows to increase milk production by 10-15%. Brand name: Posilac.
Documented risks
Butylated Hydroxyanisole: BHA is classified by the International Agency for Research on Cancer (IARC) as Group 2B (possible human carcinogen) based on studies showing it causes papillomas and squamous cell carcinomas of the forestomach in rats, hamsters, and mice at high doses. A 1983 NTP bioassay confirmed these findings. The National Toxicology Program lists BHA as 'reasonably anticipated to be a human carcinogen' in its Report on Carcinogens. The forestomach is an anatomical structure found in rodents but not humans, creating some uncertainty about direct extrapolation. EFSA's 2012 re-evaluation (EFSA Journal 2012;10(10):2588) concluded that BHA may have endocrine-disrupting potential based on animal data showing interactions with estrogen receptors and androgenic hormone pathways. EFSA found the ADI of 1 mg/kg body weight but noted concerns about endocrine effects. Japan banned BHA for use in foods containing fats and oils, consistent with its generally precautionary approach to synthetic food preservatives. In cosmetics, the EU Scientific Committee on Consumer Safety (SCCS) has assessed BHA and found potential endocrine-disrupting effects at dermal exposure levels. EWG rates BHA as high-concern in Skin Deep cosmetics database. The antioxidant paradox applies: while BHA prevents lipid oxidation in foods, it may paradoxically act as a pro-oxidant in certain biological contexts at certain doses.
Recombinant Bovine Somatotropin: See recombinant-bovine-growth-hormone-rbgh for full detail. Key concerns: rBST elevates IGF-1 in milk; elevated blood IGF-1 is associated with breast, prostate, and colorectal cancer risk in epidemiological studies. Animal welfare: increased mastitis (up to 25-50% higher rates), lameness, and antibiotic use. The Codex Alimentarius Commission declined to endorse rBST safety MRLs in a historic 33-29 vote. Health Canada rejected rBST approval in 1999 after finding it caused significant animal health problems requiring increased antibiotic use.
Scan a barcode and we'll flag both Butylated Hydroxyanisole and Recombinant Bovine Somatotropin (plus 200+ other ingredients banned overseas).
Scan free →